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ABSTRACT 
Objective: The sustained release of drug from the dosage form is useful especially for achieving controlled plasma level of the drug as well as 
improving bioavailability. The objective of the present work was to release matrix tablet of Venlafaxine HCl by using directly compressible co-
processed Excipient. 
Methods: Co-processed excipient (Chitosan 88%: eudragit s-100) was prepared in the ratio of 1:1, 1:3, and 1:5 by the solvent evaporation method. 
The sustained release matrix tablets were prepared by using Co-processed excipient by direct compression and formulate formulations such as F1to 
F9. The tablets evaluated for various physical parameters. Direct compression method followed by optimization of the evaluation parameters was 
employed to get the final optimized formulation. 
Results: The developed Co-processed excipient was characterized for DSC, FTIR, SEM and XRD which confirm the absence of any chemical changes 
during co-processing. Co-processed excipient prepared in the ratio of 1:5 showed excellent flow properties. Among all formulations, Optimized 
formulation F9 showed the desired release profile 98.7% for a period of 24 h in phosphate buffer (pH 7.4). The release co-efficient values ‘n’ (>0.5) 
indicated that the drug release followed non fickian anomalous mechanism based on formulation factors. Developed formulations were kept for 
stability study for three month as per ICH guidelines and found to be stable 
Conclusion: Developed co-processed excipient showed good drug release retarding property and could be alternate way to overcome the problems 
associated with single polymer alone. Venlafaxine HCl matrices could be developed with desirable release modulation for a once daily 
administration. 
Keyword: Co-processed excipient, Sustained release, Matrix tablet, Chitosan 88%, Eudragit s-100, Venlafaxine Hydrochloride. 
 
INTRODUCTION 
In recent time, excipients are the largest components of any 
pharmaceutical formulation [1]. The International Pharmaceutical 
Excipients Council defines excipients are the substances which 
present in a finished pharmaceutical dosage form other than the 
active drug substance [2-3]. Excipients have been appropriately 
evaluated for safety and are included in a drug delivery system to 
aid the processing of the drug delivery system during its 
manufacture, enhance stability, bioavailability, and patient 
acceptability or enhance any other attributes of the overall safety 
and effectiveness of the drug delivery system during storage or 
optimal use and having multifunctional property are provide 
pharmaceutical manufacturers with cost saving drug development 
and help in drug formulations innovation[4]. 
Now a day, most of the pharmaceutical manufacturing industries 
opting for direct compression tableting as it requires fewer 
processing steps, simplified validation, elimination of heat and 
moisture, economy, and improved drug stability compared with wet 
granulation technique. The term ‘direct compression’ (DC) is the 
process by which tablets are prepared directly from the powder 
blends of active ingredients and suitable excipients. For direct 
compression its prerequisite that excipient used for formulation 
should have good flow and compression property [5]. 
Co-processing is based on the novel concept of two or more 
excipients interacting at the sub particle level, that leads to the 
formation of excipients that granulates with superior properties 
compared with physical mixtures of components or individual 
components.[6] Usually acombination of plastic and brittle materials 
is used for co-processing. This combination prevents storage of too 
much elastic energy during the compression, which results in a small 
amount of stress relaxation and a reduced tendency of capping and 
lamination thereby optimum tableting performance. [6] The 
objective of co-processing is to provide a synergy of functionality 
improvements, also having superior intrinsic performance high 
compatibility, high intrinsic flow, good lubricating efficiency, 
improved blending properties and good binding properties [7]. 
Chitosan is a cationic polyamine with a high charge density at pH< 
6.5; and so adheres to negatively charged surface and chelates metal 
ions [8]. It is a linear polyelectrolyte with reactive hydroxyl group. 
[9] The properties of chitosan relate to its polyelectrolyte and 
polymeric carbohydrate character. The presence of the number of 
amino groups allows chitosan to react chemically with anionic 
system, which results in alteration of physicochemical 
characteristics of such combinations. The major pharmaceutical 
applications of chitosan in pharmaceutical formulations for drug 
delivery applications have been investigated in numerous studies. 
These include, Controlled drug delivery application, Rapid release 
dosage forms, improved peptide delivery, Colonic drug delivery 
system [10]. 
Eudragit S-100 are anionic Polymethaacrylates are known 
worldwide in the industry under the trade name Eudragit. These 
polymers allow the active in solid dosage form to perform during the 
passage of the human body. The flexibility to combine the different 
polymers enables to achieve the desired drug release profile by 
releasing the drug at the right place and at the right time and, if 
necessary, over a desired period of time. Other important functions 
are protection from external influences. The ratio of the free 
carboxyl groups to the ester groups is approx. 1:2 in. Eudragit S-100 
used as an enteric coating film former for solid-dosage forms [11]. 
Venlafaxine HCl is a novel third generation antidepressant drug with 
a bicyclic structure different from tricyclic, tetracyclic, or other 
commercially available antidepressants. It is a white crystalline 
solid, soluble in water (534 mg/mL). The dose of venlafaxine ranges 
from 75 to 350 mg/day. Venlafaxine and its active metabolite, O-
desmethylvenlafaxine (ODV) were proved to have improved efficacy, 
faster speed of onset of effect, and greater safety in the treatment of 
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depression, generalized anxiety disorder, and social anxiety disorder 
in adults compared with previous medicines, such as the selective 
serotonin reuptake inhibitors Venlafaxine works effectively against 
a broad range of depressive conditions, both mild to moderate and 
severe, whether occurring in in-patients or out-patients. However, 
due to the short steady state elimination half-life (3–4 h for 
Venlafaxine and 10 h for ODV), the drug has to be administered 2 or 
3 times daily so as to maintain adequate plasma levels of drug. Once 
a daily sustained release formulation developed for increasing 
patient compliance and convenience as well as a superior benefit/ 
risk ratio [13]. Thus, this work focused on the formulation and 
evaluation of matrix tablet of venlafaxine HCl by using directly 
compressible co-processed excipient comprising of Chitosan 88% 
deacylated and Eudragit S-100 by the solvent evaporation method. 
MATERIALS AND METHODS 
Materials 
Venlafaxine HCl was obtained as a gift sample from Orchid Chemicals 
And Pharmaceuticals Ltd, Aurangabad, India. Chitosan (88% deacylated) 
supplied by Everest Biotech Bengaluru., Eudragit S- 100 Evonik Degussa, 
Mumbai, India Pvt. Ltd., and Polyvinylpyrrolidone (K-30) was received 
as gift from Alkem laboratory Ltd., Mumbai. Also microcrystalline 
cellulose, magnesium stearate, Talc. All other excipients and chemicals 
used were of analytical grade (AR). 
Methods 
Preparation of directly compressible Co-processed Excipient 
The Co-processed excipient of Chitosan (88% deacylated) and Eudragit 
s-100 was prepared by using the solvent evaporation method. Chitosan 
1 gm was accurately weighed and dissolved in 15 mL of 3% v/v acetic 
acid solution . Similarly, Eudragit S- 100 (5 gm) was separately dissolved 
in 7 mL ethanol and was covered to prevent evaporation. This 
dispersion was slowly added with stirring to the Chitosan solution. The 
mixture was poured in a Petri plate and was dried at 50°C for 48 h. co-
processed excipient containing 1:1, 1 : 3,and 1: 5 ratios of chitosan: 
Eudragit S- 100 were prepared using this method. The dried co-
processed excipient was stored in a desiccator until used [14]. 
Characterization of co-processed excipient 
Fourier transforms infrared spectroscopy (FTIR) 
Co-processed excipient discs were prepared by pressing the Co-
processed excipient with potassium bromide and the spectra 
between 4000to 400 cm-1was recorded using FTIR 
spectrophotometer (SHIMADZU 84500 S, Tokyo, Japan)[15]. 
Differential scanning calorimetry (DSC)  
DSC analysis was performed using Shimadzu-Thermal Analyzer DSC 
60 on 2-5 mg sample was taken in the quantity of 2 to 4 mg. Samples 
were heated in an aluminum pan at a rate of 10°C / min within a 30 
to 300°C temperature range under a nitrogen flow of 10 ml/min. An 
empty sealed pan was used as a reference [16]. 
X ray Diffractometry (XRD) 
Approximately 100 mg of the sample was exposed to Cu radiation 
wavelength 1.5406 A°, having temperature rang 170 °C to +450 °C in 
a wide-angle powder X-ray diffract meter (Make/Model-Bruker AXS 
D8 Advance). The instrument was operated in the step-scan mode, 
in Max. Use angular range is 3° to 135°. 
Scanning electron microscopy (SEM) 
Scanning electron microscopy (SEM) is a method for high resolution 
surface imaging. The SEM uses an electron beam for surface 
imaging.(SEM Make JEOL Model JSM - 6390LV) double-sided carbon 
tape was affixed on aluminum stubs over which the powder sample 
of Co-processed excipient samples was observed for morphological 
characterization using a gaseous secondary electron detector. 
Powder flow properties of co-processing excipients  
The following micromeritic properties of the co-processed 
excipients were studied. 
Bulk and tapped densities  
7.5 g of the blend were carefully poured into a 50 ml graduated 
cylinder. The volume occupied by the blend was read and the bulk 
density calculated in gm/ml. The cylinder containing the blend was 
tapped until constant volume was obtained using bulk density 
apparatus from a height of 2 cm and the tapped density calculated in 
gm/ml. 
Percentage compressibility (Carr’s index) and Hausner’s ratio 
The percentage compressibility (CI) was calculated from the 
difference between the tapped (Td) and the bulk densities (Bd) 
divided by the tapped density and the ratio expressed as a 
percentage. The Hausner’s ratio (HR) is the ratio between the 
tapped and bulk density.  
CI= (Tapped density – Bulk density)/ Tapped density× 100 
HR= Tapped density/Bulk density 
Drug –Excipient compatibility study 
FTIR study 
To analyze the compatibility of drug with polymers, the infrared 
spectrum of pure venlafaxine HCl sample and its combination with 
excipients mixture was recorded using FTIR spectrophotometer 
(SHIMADZU 84005). The scanning range was 4000 to 400 cm-1. A 
change in spectrum pattern of drug due to presence of polymers was 
investigated to identify any chemical interaction [15]. 
DSC study 
The possibility of drug–excipient interaction was further 
investigated by differential scanning calorimetry (DSC). DSC analysis 
was performed using Mettler Star SW 9.01 DSC- 60(SHIMADZU). 
DSC of pure Venlafaxine HCl alone and its combination with 
excipients mixture was taken in the quantity of 2 to 4 mg sample 
Samples were heated in an aluminum pan at a rate of 10°C / min 
within a 30 to 300°C temperature range under a nitrogen flow of 10 
ml/min. An empty sealed pan was used as a reference. 
Preparation of Matrix tablet of Venlafaxine HCl 
Matrix tablets of Venlafaxine HCl, each containing80 mg [15]. 
Venlafaxine HCl was prepared by using Co-processed excipient by 
direct compression method. The composition of various 
formulations was shown in [Table 1]. Polymer composition was 
selected on the basis of trial taken for the formulated preparation. 
All the ingredients weighed accurately, passed through 60 mesh and 
mixed in geometric order. Mixing was continued for 10 min to 
achieve uniform mixing then the mixture was lubricated with 
magnesium stearate for 5 min. Different polymers were used alone 
or in combination to formulate matrix tablet of Venlafaxine HCl. The 
lubricated blend was then compressed into a tablet using 10 mm 
standard round shaped punches on 10 station tablet compression 
machine JM-10 (JAGUAR Co. Pvt. India). Each tablet contains 80 mg 
of Venlafaxine HCl base and total weight of a tablet was 300 mg 
depending upon polymer concentration. All the tablet formulations 
were stored in air tight container till further use. 
Evaluation of powder blends 
The powder blends were evaluated for flow property (angle of 
repose), loose bulk density, tapped density, compressibility index 
and drug content. Angle of repose was determined by fixed funnel 
method. Loose and tapped density was determined by cylinder 
method and for Carr’s Index (CI) value following equation was used:  
Carr’s Index = tapped bulk density-loose bulk densityx100/tapped 
density. Hausner’s ratio was also calculated to define the flow 
property. A Hausner’s value between 1.12 to 1.25 is indication of 
good flow property. 
Evaluation of tablets 
The prepared tablets were evaluated for their physical parameters 
like hardness, thickness, weight variation, friability and drug 
content. For hardness testing Monsanto hardness tester and for 
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frability Roche friabilator (Campbell Electronics, Mumbai, India) was 
used to determine the value. Vernier caliper was used to measure 
the thickness of the tablets. Weight variation was performed as per 
official method. 
Drug Content Estimation 
Twenty tablets were selected randomly and the average weight was 
calculated. Tablets were crushed in a mortar and accurately average 
weighed amount of tablets triturate was taken for analysis. Samples 
were transferred to different volumetric flasks and were diluted up 
to the mark using phosphate buffer (pH 6.8). The content was 
shaken well and kept for 30 minutes for dissolving the drug 
completely. The mixtures were filtered and appropriate dilutions 
were made. The drug content in each tablet was estimated at λ max 
225 nm against blank as reference. 
In vitro dissolution studies 
In vitro drug release study of the samples was carried out using USP 
– type II dissolution apparatus (Paddle type). The dissolution 
medium, 900 ml of 1.2 pH HCl buffer (2 hours) and 6.8 pH phosphate 
buffer (22 hours) for 24 hours, was placed into the dissolution flask 
maintaining the temperature of 37 ± 0.50C and rpm of 50. The 
apparatus was allowed to run for 24 hours. Samples measuring 5 ml 
were withdrawn after every 1 hour up to 24 hours manually. During 
sampling, samples were filtered.  
The fresh dissolution medium was replaced every time with the 
same quantity of the sample. Collected samples were analyzed at 
225 nm using phosphate buffer (pH 6.8) as blank. The cumulative 
percent drug release was calculated and the graph was plotted 
between cumulative percent drug release verses time (h) [20-21]. 
Kinetic analysis of release data 
To describe the kinetics and percent releases of the drug release from 
sustained release matrix Venlafaxine HCl formulation (trial batches). 
The drug release data from trial batches were fitted in to various 
kinetic release mathematical models such as zero order, first order, 
Higuchi, Korsmeyer-Peppas models by using PCP-Disso-v3 software. 
The regression coefficient (r2) value compared to each other and 
selected best fit model, the release mechanism of matrix tablet 
formulation from system was decided from release exponent value. 
 
Table 1: Composition of formulations of matrix tablet of Venlafaxine HCl 
Ingredients (mg/tablet) Formulation Code 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
Venlafaxine HCl 80 80 80 80 80 80 80 80 80 
PVP K30 25 25 25 50 50 50 75 75 75 
C0-processed excipient 40 52.5 65 40 52.5 65 40 52.5 65 
MCC 125 112.5 100 100 87 75 75 62.5 50 
Magnesium Stearate 15 15 15 15 15 15 15 15 15 
Talc 15 15 15 15 15 15 15 15 15 
Total Weight 300 300 300 300 300 300 300 300 300 
 
The zero-order kinetic describes the system in which the drug 
release rate is independent of its concentration. The first order 
kinetic describes the system in which the drug release rate is 
concentration dependent. Higuchi describe the release of drug from 
an insoluble matrix as square root of time dependent process. The 
Hixon-Crowell cube root law describes the drug release from the 
system in which there is change in the surface area and the diameter 
of particles present in dosage form. Korsmeyer-Peppas Equation 
(Diffusion/Relaxation Model) Mt/M0 = k5tn[18,19] 
• Zero order Kinetics Q = K0t  
• First order Kinetics Log C = Log C0-Kt/2  
• Higuchi’s Square root of time Equation (Diffusion model) Q = Kt½ 
• Hixon-Crowell cube root Equation (Erosion model) (100-W) 1/3 = 
1001/3– k3t  
Stability study 
Stability studies were carried out as per ICH Q1A guidelines. The 
optimized Venlafaxine HCl tablets of F9 batch were wrapped in 
aluminium foils and were placed in the environmental stability 
chamber at 400C±20C/75%±5% RH for a period of three month. 
Sampling was done at a predetermined time intervals of initial, 1 
month, 2 month, and 3 month. The formulation was analyzed for 
organoleptic characteristics, hardness, drug content, disintegration 
time and dissolution profile [20]. 
RESULTS AND DISCUSSION 
Characterization of Co-processed excipient 
FTIR spectroscopy is a quick and simple technique for identifying 
any chemical changes or interaction. FTIR spectra of Chitosan 
showed characteristic peak at 1157.0 cm-1 due to C-O stretchingand 
N-H stretching at 1658.44 cm-1. A bending vibration at 1419.66 cm-
1 was observed due to CH3 bending. FTIR spectra of eudragit s-100 
exhibits –OH vibrational stretching at 2592.41 cm-1, due to 
carboxylic acid group, the C=O stretching ester group was found at 
1720.56 cm-1. The band present at 1450.52 cm-1, indicating CH3 
bending. As shown in Figure 1. FTIR spectra of co-processed 
excipients showed retention of all the major peaks of individual 
polymer which indicate absence of chemical interaction between 








Fig. 1: FTIR Spectra of Chitosan (A), Eudragit s-100 (b) and Co-
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DSC is a useful tool for characterizing a particular polymer based on 
its exothermic and endothermic thermal transitions. DSC thermo 
grams of chitosan, eudragit s-100 and (chitosan-eudragit s-100) Co-
processed excipients are shown in Figure 2. The DSC thermogram of 
co-processed excipient exhibits sharp endothermic peak at 244.31 
which was corresponding to its melting with decomposition and 
indicating its crystalline nature and purity of sample. DSC 
thermogram of co-processed excipients shows no additional 
endotherm peaks which suggest that developed co-processed 

















File Name: Hirew Sir Chitosan 2.tad
Detector: DSC-60






Temp Rate Hold Temp Hold Time
[C/min ] [  C   ] [  min  ]
10.00 360.0 0








Fig. 2: DSC thermogram of Chitosan (A), Eudragit s-100 (b) and 
Co-processed excipient (C) 
 
The x-ray diffraction patterns of Chitosan, Eudragit s-100, Co-
processed Chitosan: Eudragit s-100 has shown in Figure 3. The 
amount of Co-processed Chitosan: Eudragit s-100 was found 98.90 
% amorphous, Chitosan 85.7% amorphous And Eudragit s-100, 








Fig. 3: X-ray diffraction pattern of Chitosan (A), Eudragit s-100, 
and Co-processed excipient (C) 
 
Were also in one range, so no structural changes were found. The x-
ray diffraction pattern has shown the diffused pattern indicating the 
amorphous nature. It has also shown the diffused pattern indicating 
the co-processed Chitosan with Eudragit S-100 was present in the 
amorphous state. Hence, it was concluded that the polymorphic 
characteristic of Chitosan, Eudragit s-100 and their interaction was 
not changed. 
Scanning electron microscopy (SEM) was used to investigate particle 
surface morphology when comparing the surface of chitosan and 
eudragit s-100 (1:5) mixture with the surface of co-processed 
excipient (chitosan: eudragit s-100, 1:5) prepared using solvent 
evaporation method. It is apparent that its native structure has 
changed from a smooth, flat surface structure, with folded edges, to 
three-dimensional compacts for the eudragit s-100. This folding in 
the surface of the co-processed chitosan-eudragit s-100 creates a 
bigger surface area which can accommodate a larger quantity of 






Fig. 4: Scanning electron micrograph of mixture of Chitosan + 
Eudragit s-100 (1:5) ratio (A) and of prepared co-processed 
excipient by solvent evaporation method (B) 
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Physical properties of material to be used as an excipient in direct 
compression formulations are of critical importance. Therefore, 
physical processes such as mixing, bulk particle movement and 
compaction are mainly depending on the powder particle 
characteristics.  
The efficiency of flowability of a direct compressible excipient in 
automated technology employing rotary compression system is essential 
for production of tablets with uniform weight. The flow and 
compressibility characteristics of co-processed excipient were indirectly 
assessed by determining their bulk density, tapped density, angle of 
repose and Carr’s compressibility indices and hausner’s ratio.  
Results depicted in [Table 3], suggested that all the co-processed 
excipients have improved flow ability and compressibility. Co-
processed excipient prepared in Chitosan and Eudragit s-100 ratio 
of 1:1, 1:3 and 1:5.  
But result of ratio 1:5 showed good flow properties and 
compressibility as compared to other ratios of selected 
combinations. The optimized ratio 1:5 also showed good tableting 
properties as shown in [Table 3]. The compatibility study was 
carried out to find out compatibility between drug and excipients 
used in the formulations. The FT-IR spectrum of the pure drug 
Venlafaxine HCl, Venlafaxine HCl with PVP K30, Venlafaxine HCl with 
Co-processed excipient, and combination of Venlafaxine HCl matrix 
tablet formulation are compared with standard spectrum and 
characteristic band observed as shown in Figure 5. The 
characteristic bands of Venlafaxine HCl were found at 1388.65 cm-1 
(C-H Bending) 1493.3 cm-1 alcohol (C-0 Stretching) 1610.8 cm-1 
amine (N-H Bending), 2933.53 cm-1(C-H Stretching) 3326.98 cm-1(0-
H Stretching) due to presence of hydroxy, amine and functional 
group and aromatic ring in the structure of Venlafaxine HCl was 
shown in Figure 5. 
 
Table 2: Angle and d values in XRD 
S. 
No. 
chitosan: eudragit S-100 
(Co-Processed excipient) 
Native Chitosan Native Eudragit S-100 
Angle d value Angle d value Angle d value 
1 12.984 7.022 9.651 8.651 12.205 6.609 
2 13.211 6.697 6.351 7.637 16.551 5.356 
3 15.306 5.782 15.386 6.695 17.857 4.964 
4 18.023 4.911 18.301 20.236 18.882 4.694 
5 19.036 4.626 20.651 21.653 21.732 3.742 
6 22.324 3.971 33.213 26.382 23.715 2.781 
 
Table 3: Powder flow properties of co-processed excipient 
S. 
No 










1 Chitosan+Eudragit S-100 ratio 1:1 1.111 1.25 11.12 % 1.125 22.82 
2 Chitosan+Eudragit S-100 ratio1:3 0.1144 0.1960 11.02 % 1.123 25.46 










Fig. 5: FTIR spectrum of Venlafaxine HCl (A), Venlafaxine 
HCl+PVP K30 (B), Venlafaxine HCl +Co-processed excipient (C) 
and physical mixture 
 
The characteristic peak of Venlafaxine HCl with PVP K30were found 
at 1377.08 cm-1 (C-H Bending) 1039.92 cm-1 alcohol (C-O Stretching) 
1614.31 cm-1 amine (N-H Bending), 2929.67 cm-1(C-H Stretching) 
3325.05 cm-1(OH Stretching). The spectrum of Venlafaxine HCl with 
Co-processed excipient shows that at 1396.37 cm-1 (C-H Bending) 
1039.36 cm-1 alcohol (C-O Stretching) 1612.37 cm-1 amine (N-H 
Bending), 2929.67 cm-1(C-H Stretching) 3325.05 cm-1(OH 
Stretching). The physical mixture shows that all the principle peak of 
Venlafaxine HCl in physical mixture were preserved and shows at 
1375.15 cm-1 (C-H Bending) 1031.85 cm-1 alcohol (C-O Stretching) 
1614.31 cm-1 amine (N-H Bending), 2929.67 cm-1(C-H Stretching) 
3325.07 cm-1(OH Stretching). Hence, we can conclude that there was 
no interaction of drug and excipients. 
Thermal analysis of drug and its mixture were carried out using DSC. 
The DSC thermogram of Venlafaxine HCl and its mixture showed 
sharp endothermic peak at 207.42 °C corresponding to its melting 
with decomposition and indicating its crystalline nature. The DSC 
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thermogram of plain Venlafaxine HCl and its mixture is given in 
Figure 6 and Figure 7. The study showed and confirmed that there is 
no interaction of Venlafaxine HCl with other selected excipients.  
 
 
Fig. 6: DSC thermogram of Venlafaxine HCl 
 
Fig. 7: DSC thermogram of drug and physical mixture of 
excipient 
 
The powder flow characteristics of drug affect formulation of tablets. 
The result was shown in [Table4] indicated that the powder blend 
has good flow property. 
 
Table 4: Blend flow properties of of Venlafaxine HCl tablet formulation 
S. 
No. 
Formulation Angle of Repose Bulk density Tapped Density Carr’s Index Hausner’s Ratio 
1 F1 22.08±0.30 0.3605 0.4410 18.25 1.22 
2 F2 19.95±0.28 0.3947 0.4466 16.70 1.05 
3 F3 19.52±0.31 0.3948 0.4414 10.65 1.11 
4 F4 21.06±0.42 0.3947 0.4681 15.66 1.18 
5 F5 22.10±0.52 0.3750 0.4166 9.98 1.11 
6 F6 20.96±0.16 0.4166 0.4682 10.98 1.12 
7 F7 18.79±0.28 0.3940 0.4413 10.65 1.12 
8 F8 19.40±0.33 0.3801 0.4217 9.73 1.10 
9 F9 18.60±0.58 0.3637 0.4231 4.47 1.04 
 
All formulations batches F1 to F9 were evaluated for physical 
properties such as tablet hardness, weight variations, thickness, 
diameter and drug content by reported method and found to be in 
Pharmacopoeial acceptable range. The matrix tablet formulations 
were prepared using directly compressible coprocessed excipient 
with composition of 1:5 ratio of chitosan and eudragit s-100 From 
[Table 5], it was observed that thickness of the tablets for all the 
formulations was found to between 3.33 mm to 3.46 mm, the 
maximum standard deviation in thickness was up to 0.028 mm. The 
hardness of the tablets was found to be in the range 6.7 kg/cm2. The 
friability of the tablets for all the formulations was found to be 
between 0.716 % and 1.00 %.  
The average weight of the tablets from all the formulation was found 
to between 298.33 mg to 302.40 mg.% drug content for all 
formulation was found to between 98.0 % and 100.02 %. 
  













 F1 3.38± 0.028 7.0±0.92 0.716 302.40±0.89 98.0% 
 F2 3.44± 0.016 7.2±0.37 0.886 298.58± 0.68 97.53% 
F3 3.33± 0.024 7.46±015 0.977 300.77± 0.73 99.18% 
 F4 3.43± 0.024 7.4±0.10 0.73 298.06± 0.69 98.59% 
 F5 3.38± 0.012 6.7±0.25 0.99 300.83± 0.88 99.82% 
 F6 3.38± 0.032 7.0±0.50 1.00 299.50± 0.69 98.35% 
 F7 3.41± 0.0081 6.9±0.26 0.76 299.20± 0.70 99.77% 
 F8 3.46± 0.0081 7.2±0.025 0.867 298.65± 0.70 99.88% 
 F9 3.35± 0.024 7.3 ±0.34 0.829 298.69± 0.41 100.0% 
Data represented as mean ± Std. Dev. with n=3, Where n= Number of replicates 
 
Table 6: Kinetic treatment of prepared Venlafaxine HCl matrix tablets 
Formulation Code Zero Order 
(R2) 
First Order (R2) Hixson Crowell (R2) Higuchi (R2) Korsmeyer Peppas 
(R2) (n) 
F1 0.9455 0.9328 0.966 0.9894 0.9447 0.4891 
F2 0.9651 0.9548 0.9577 0.9993 0.9489 0.6297 
F3 0.9577 0.9436 0.9463 0.9781 0.9138 0.5504 
F4 0.9762 0.9704 0.9723 0.9883 0.9113 0.4688 
F5 0.9522 0.9809 0.9822 0.9904 0.9206 0.4812 
F6 0.9513 0.9784 0.9801 0.994 0.9279 0.5028 
F7 0.9594 0.9363 0.9354 0.9931 0.9551 0.4753 
F8 0.949 0.9513 0.9467 0.9953 0.9458 0.4716 
F9 0.9497 0.9529 0.9548 0.9934 0.9226 0.6485 
[Table 7] the thickness of optimized F9 formulation was found to be in the range of 3.35- 3.37 mm. Tablet weight was found to be in the range of 
298.23-300.77 mg. Hardness of tablets was found to be in the range of 5.20-5.36 kg/cm2. Content uniformity was found to be in the range of 98.86- 
99.56 %. 
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Table 7: Evaluation of formulation (F9) kept for stability at 400C /75%RH 
Parameter 1 Month 2 Month 3 Month 
Appearance White Color White Color White Color 
Thickness (mm) 3.37 3.37 3.35 
Hardness (Kg/cm2) 5.36 5.36 5.20 
Weight of tablet 300.77 299.60 298.23 
λ max (nm) 225.00 225.00 225.30 
Drug content (%) 99.40 99.56 98.86 
The stability dissolution profile optimized F9 formulation are depicted in the Figure 9, Short-term accelerated stability data obtained for optimized 
formulation revealed that drug content, thickness, hardness, in-vitro dissolution were not significantly changed under accelerated storage condition 
of 40 0C ± 2 0C / 75% ± 5 % RH 
 
The dissolution studies were carried out for all nine formulations i. 
e. F1 to F9 was shown in Figure 8. Drug content of each tablet was 
80 mg and 900 ml of dissolution medium was used for dissolution 
studies. Maintaining sink condition is important during the 
dissolution experiment for consistent and accurate measurement of 
the dissolution rate. Figure.8, it was observed that F9 formulation 
was found to be optimized formulation and release the drug up to 
98.70% for 24 h in a sustained manner as compared to other 
formulations. 
The dissolution data of batches F1 to F9 was fitted to Zero order, 
First order, Higuchi and Korsmeyer - peppas models [Table 6]. The 
preference of a certain mechanism was based on the correlation 
coefficient “r”for the parameters studied, where the highest 
correlation coefficient is preferred for the selection of the 
mechanism of release. The highest “r” value was obtained for 
Higuchi model, so it followed diffusion was the predominant release 
mechanism for matrix tablets results were in [Table 6]The value of 
release exponent“n” obtained from Korsmeyer equation was greater 
than 0.5 for F9- 0.6485 indicate Non -Fickian transport so the final 
mechanism of drug release was swelling or chain relaxation of 
polymers followed by diffusion and erosion and the drug releases by 
first order phenomenon as there was continuous increase in percent 
cumulative drug release up to 24 hours. 
 
 




Fig. 9: Stability profile F9 (3 Month) 
 
CONCLUSION 
Based on the studies it was concluded thatCo-processed excipients 
(chitosan: eudragit s-100) were prepared in ratio 1:1, 1:3 and 1:5 by 
using Solvent evaporation method. The developed co-processed 
excipients were evaluated for Compressibility index (Carr’s index), 
Hausner’s ratio and Flow properties (Angle of Repose). The 
prepared co-processed excipient in the ratio of 1:5 showed excellent 
flow properties as compared to other ratio and native excipient like 
chitosan and eudragit s-100. Hence co- processed excipient in ratio 
1:5 was select and use in sustained release matrix tablet of 
Venlafaxine Hydrochloride and evaluated for Pre-compression 
parameter such as bulk density, tapped density, Carr’s index, 
Hausner’s ratio, Angle of repose, and Post- compression parameter 
such as hardness, thickness, friability, weight variation, In-vitro drug 
release. Developed co-processed excipient showed good drug 
release retarding property and could be alternate way to overcome 
the problems associated with single polymer alone. 
All the prepared formulation shows satisfactory organoleptic 
properties. Drug content of all the developed formulations was 
found within limits i. e. 98-101%. Once daily matrix tablets of 
Venlafaxine HCl were prepared using Co-processed excipient and, 
PVP K-30. The presence of PVP K30 reduces initial swelling of co-
processed excipient and retards the drug release up to 24 hours. The 
presence of Co-processed excipient sustains the drug release due to 
formation of gel layer around the tablet and PVP K30 releases drug 
slowly over prolong period of time by forming pores. This 
investigation clearly indicates that the combination of PVP K30 and 
Co-processed excipient could be used as retardant of drug release 
for a period of 24 hours. Various tablet evaluation parameters like 
thickness, hardness, friability, weight variation and drug content of 
all formulations were found to be satisfactory. Dissolution study 
revealed that formulations F9 release the drug up to 24 hours. All 
formulations showed Higuchi drug release kinetics. All formulation 
followed zero order kinetics. All formulations were fitted in 
Korsmeyer Peppas equation. The releases exponent ranges between 
0.40-0.70. The optimized formulation (F9), in short-term accelerated 
testing done for three months at 400C, there has been no significant 
difference in dissolution profile, drug content, hardness and physical 
appearance so formulation should be stable. Venlafaxine HCl 
matrices could be developed with desirable release modulation for a 
once daily administration. 
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